GLPwatch
Papers (10409)
Page 115 of 174, ranked by citation count.
- Liraglutide for Adolescents with Obesity.
- Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.
- Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.
- Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria.
- Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
- In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae.
- Pre-pregnancy treatment of semaglutide improves high-fat-diet-induced placental and fetal hypothalamic alterations in a sex-specific manner in rats†.
- One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.
- Use of PASEF for Accelerated Protein Sequence Confirmation and De Novo Sequencing with High Data Quality.
- Semaglutide ameliorates metabolic disorders in offspring via regulation of oocyte ROS of pre-pregnancy obesity mice.
- Obesity update: cardiovascular risk and therapeutic innovations (focus on semaglutide and tirzepatide).
- The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.
- Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.
- Combination of exendin-4 and DPP-4 silencing promoted angiogenesis of human coronary artery endothelial cells via activation of PI3K/Akt pathway.
- Subcutaneous Semaglutide Use for Weight Management: Practice and Attitudes of Physicians in Israel.
- Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD.
- Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
- A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.
- Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.
- A Pair of Siblings With Wolfram Syndrome: A Review of the Literature and Treatment Options.
- Treatment of obesity with GLP-1 receptor agonist after bariatric surgery: Real-world evidence.
- Semaglutide (Ozempic) for Type 2 Diabetes Mellitus.
- Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management.
- Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.
- Semaglutide attenuates lipotoxicity-induced cardiac injury by inhibiting Slc27a2 expression.
- Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells.
- Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide.
- Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis.
- Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists.
- Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial.
- Liraglutide for adults living with obesity.
- The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.
- Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
- A novel antihypertensive effect of exenatide, a GLP-1 agonist.
- Exploring Glucagon-Like Peptide-1 Receptor Agonists Usage Among Non-Diabetic Healthcare Providers: A Cross-Sectional Multi-Country Study.
- Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
- Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review.
- Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study.
- Exenatide ER-induced eosinophilia.
- Combined effects of voluntary running and liraglutide on glucose homeostasis, fatty acid composition of brown adipose tissue phospholipids, and white adipose tissue browning in db/db mice.
- Semaglutide and Tirzepatide to Treat Obesity.
- Exenatide stimulates solute-free water clearance by the rat kidney in hyperhydration.
- A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet.
- Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.
- Treatment of Type 2 Diabetes in Patients with Obesity: A Review.
- Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial.
- Contractile effects of retatrutide in isolated mouse atrial preparations.
- Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.
- Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
- Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
- Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study.
- Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling.
- Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages.
- GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.
- Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.
- Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.
- Semaglutide is safe and efficacious for NASH resolution.
- Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes.
- Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
- A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.